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Abstract
Background: To investigate the anti-inflammatory effects of specific small interfering RNA targeting NF-κB on
lipopolysaccharide (LPS)-induced acute lung injury (ALI) in rats.
Method: Acute lung injury was induced in Sprague-Dawley rats by intraperitoneal injection with LPS (5 mg/kg),
followed by immediate intratracheal instillation of siRNA targeting NF-κB p65 (40 μg/ml). Animals in each group
were sacrificed at 1 h or 8 h after the instillation. Pulmonary histological changes were evaluated by hematoxylin-eosin
staining. The levels of NF-κB and TNF-α were measured by qRT-PCR. Expressions of NF-κB in lung cells and TNF-α in
bronchoalveolar lavage fluid (BALF) were determined by western blot analysis and enzyme-linked immunosorbent
assay (ELISA) respectively.
Results: LPS administration reduced the rectal temperature and white blood cell counts at 1 h, increased lung wet/dry
weight ratios, caused evident lung histopathological injury, and increased the detectable transcript and cytokine levels
of TNF-α in lung tissue in BALF. siRNA targeting of NF-κB p65 effectively abrogated the expression of NF-κB p65 in lung
cells and, aside from rectal temperatures, ameliorated all changes induced by LPS.
Conclusions: NF-κB knockdown exerts anti-inflammatory effects on LPS-induced ALI especially in the initial phase,
which may be due in part to reduced levels of the proinflammatory cytokine TNF-α. NF-κB siRNA’s rapidity
and effectiveness to abrogate ALI development may provide an effective therapeutic method with future
clinical applications.
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Background
Acute lung injury (ALI) and its severe manifestation,
acute respiratory distress syndrome (ARDS), are well-
defined clinical disorders characterized by severe hypox-
emia, pulmonary edema and neutrophil infiltration.
Among many clinical insults, sepsis represents one of
the main cause of ALI. Unfortunately, the significant
breakthrough in ALI diagnosis and therapy strikes a
sharp contrast with its high morbidity and mortality
[13]. This discrepancy can only be eliminated through
the discovery of novel and effective pharmacological
methods, which remain unsatisfactorily absent, especially
in the initial phase of ALI.
Nuclear factor kappa B (NF-κB) is an evolutionarily
conserved family of DNA binding proteins involved in
transcriptional regulation of many gene products. Ac-
tivation of the NF-κB pathway is a trigger that may
initiate an inflammatory cascade and leads to the up-
regulation of many pro-inflammatory cytokines [15].
NF-κB regulates the expression of these cytokines by
directly binding to the consensus sequences in their
enhancer/promoter regions [5, 6, 8]. In addition, activa-
tion of NF-κB can be induced in response to lipopolysac-
charide (LPS), tumor necrosis factor-α (TNF-α),
interleukins, radiation and other stimulating agents. Im-
portantly, the activation of NF-κB is observed in alveolar
macrophages from patients with ARDS [18], indicating
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the implication of NF-κB pathway in the development and
progression of ALI and ARDS. Therefore, determining
whether pharmacologic inhibition of the NF-κB pathway
inhibits the development and progression of ALI may pro-
vide a novel more effective therapeutic option for treat-
ment of this disease.
Many attempts to target various key components of
the classical activation pathway have been made in re-
cent years. These include the inhibition of ubiquitination
and proteosomal degradation of inhibitor of kappa B
(IκB) and blocking of activated NF-κB’s binding to DNA
but proved to be impractical in a clinical setting due
largely to lack of specificity or necessity of pretreatment
before insults. siRNA with high specificity, however, can
target and decompose the complementary NF-κB mRNA
[9], making it a perfect candidate for inhibiting the ini-
tially inflammatory cascade during ALI development via
inhibition of NF-κB pathway activation.
In the present study, we undertook the challenge of
determining whether targeted depletion of NF-κB could
block the development and progression of LPS-induced
ALI in rats without the necessity of pretreatment. More-
over, we wanted to determine how inactivation of the
NF-κB pathway contributed to the suppression of the in-
flammation. Our results show that siRNA depletion NF-
κB is directly responsible for decreased levels of TNF-α
and reduces the pathology of ALI.
Methods
Animals use approval and reagents
Sprague-Dawley rats weighing 100–150 g were pur-
chased from the Experimental Animal Center of the
Southern Medical University (Guangzhou, China). All
animals were allowed food and tap water ad libitum and
exposed to a 12 h light/12 h dark cycle in accordance
with the Principles of Laboratory Animal Care approved
by Southern Medical University. LPS (O111:B4) was pur-
chased from Sigma Chemical Company (St. Louis, MO.,
USA) and dissolved in 0.9% saline before use. SYBR Pre-
mix Taq™ kit was purchased from TaKaRa Biotechnology
Co., LTD (Shiga, Japan). Tissue protein extraction re-
agent was purchased from TaKaRa Biotechnology Co.,
LTD (Shiga, Japan). Antibody specific for total NF-κB
p65 subunit was purchased from Abcam (Cambridge,
MA., US). Enzyme-linked immunosorbent assay (ELISA)
kit of TNF-α was purchased from Thermo Scientific
Pierce Protein Research Products (Rockford, IL., USA).
RNA interference
Three siRNAs targeting NF-κB were synthesized by
Shanghai GenePharma Co., LTD (Shanghai, China). All
siRNAs (sense: 5′-GGA GUA CCC UGA AGC UAU
AUU-3′; antisense: 5′- UAU AGC UUC AGG GUA
CUC CUU -3′) were tested on lung tissue cells to
choose the one with the highest gene silencing efficacy
for further use. The scrambled siRNA (sense: 5′-UUC
UCC GAA CGU GUC ACG UUU-3′; antisense: 5′-ACG
UGA CAC GUU CGG AGA AUU-3′) was used as con-
trol. All siRNAs were dissolved by DEPC-treated water
to a final concentration of 40 μg/ml.
Construction of LPS-induced ALI models
According to individual weights, SD rats were intraperi-
toneally injected with 5 mg/kg LPS dissolved in 2 ml
sterile saline with a 20 gauge-needle syringe to establish
ALI models. Since LPS administration can cause neutro-
phil infiltration, interstitial edema, hemorrhage and pro-
inflammatory cytokine production, which effectually
simulates the natural development of ALI, it provides us
with an optimal platform to test siRNA efficacy.
Experimental protocol
All SD rats were randomly assigned to one of the follow-
ing four groups (n = 12, each group). Saline + DEPC
group received an intratracheal instillation of 1.5 ml
DEPC-treated water immediately after an intraperitoneal
injection of 2 ml saline. LPS + DEPC group received an
intratracheal instillation of 1.5 ml DEPC-treated water
immediately after LPS administration. LPS + scramble
group received an intratracheal instillation of 1.5 ml
scramble RNA (40 μg/ml) immediately after LPS admin-
istration. LPS + siRNA group received an intratracheal
instillation of 1.5 ml siRNA (40 μg/ml) immediately after
LPS administration. Six rats in each group were ran-
domly sacrificed at 1 h and 8 h after the instillation
respectively. Rectal temperatures were measured be-
fore both LPS injection and then sacrifice. Rectal
temperature changes were calculated by taking the
rectal temperature at time of sacrifice and subtracting
the rectal temperature before LPS injection. Right
lung was lavaged to collect bronchoalveolar lavage
fluid (BALF). Then the lower lobe of right lung was
rapidly excised and preserved in the liquid nitrogen
for subsequent tissue RNA and protein extraction.
The superior lobe of left lung was used for histo-
pathological examination. The lower lobe of left lung
was excised for analysis of lung wet/dry weight ratios.
Blood samples were collected from iliac artery. The
rats were anesthetized by chloral hydrate (3.5 ml/kg)
throughout the surgical procedures.
Bronchotracho alveolar lavage (BAL)
Animals were anesthetized by intraperitoneal injection
of chloral hydrate (3.5 ml/kg) and fixed on a board in a
supine position. After sterilization, a median sternotomy
was performed to expose both of lungs and trachea. The
hilum of the left lung was ligated, and then the right
lung was lavaged twice with 5 ml ice-cold phosphate
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buffered saline (PBS). Each time, 4.5 ml of the injected PBS
was recovered. The collected BALF was immediately cen-
trifuged at 500 × g for 10 min at 4 °C, and the cell-free
supernatant were stored at -80 °C until TNF-α concentra-
tion assay. The concentration of TNF-α in BALF was quan-
tified by enzyme-linked immunosorbent assay (ELISA)
according to the manufacture’s recommendations.
Histopathological examination
The superior lobe of left lung of each rat was harvested
when rats were sacrificed, fixed in 10% neutral buffered
formalin for 24 h, and embedded in paraffin. Tissues were
cut into a series of microsections (4 μm), and then stained
with hematoxylin-eosin using standard protocols.
Lung wet/dry weight ratio
As an indication of lung edema, the lung wet/dry weight
ratio was calculated by dividing the wet weight by the
dry weight. The lower lobe of the left lung was excised
and weighed to obtain the wet weight. After drying in an
oven at 80 °C for 24 h, the lobe was weighed again to
obtain the dry weight.
Western blot analysis
The lower lobe of the right lung was harvested and
stored in −80 °C liquid nitrogen. After homogenization
of tissue samples, total proteins were extracted and their
concentrations were measured by BCA protein assay.
Cell lysates (20 μg protein/lane) were separated on 10%
SDS polyacrylamide gel electrophoresis and transferred
to polyvinylidene difluoride membranes, which were
subsequently blocked with 5% skim milk in a PBST solu-
tion (100 mM NaCl,50 mM Tris,0.1% Tween-20,PH
7.5)for 1 h at room temperature and probed overnight at
4 °C with appropriate primary antibodies. Horseradish
peroxidase (HRP) conjugated anti-rabbit IgG and anti-
rat IgG were used as secondary antibodies according to
the primary antibodies. Immunoreactive bands were vi-
sualized by enhanced chemiluminescence.
Total RNA extraction and qRT-PCR
The lower lobe of the right lung was harvested and stored
in −80 °C liquid nitrogen. Total RNA was extracted from
tissue samples using Trizol reagent. 2 μl of total RNA from
each sample in a final reaction volume of 10ul was
converted into single-stranded cDNA using SuperScript II
Reverse Transcriptase (Invitrogen) following the manufac-
turer’s recommendations. The RT PCR reaction was carried
out with 37 °C for 15 min and 85 °C for 50 s. qRT-PCR was
performed using SYBR Premix Taq™ kit with the 95 °C acti-
vation step for 30 s; 95 °C denaturation step for 5 s, 62 °C
annealing step for 30 s (NF-κB) or 58 °C annealing step for
30 s (TNF-α), 72 °C extension step for 34 s for 40 cycles;
and a final extension step of 72 °C for 4 min. The following
primers were used: NF-κB forward: 5′-GGG ACT ATG
ACT TGA ATG CGG TCC -3′, reverse: 5′-CAG GTC
CCG TGA AAT ACA CCT CAA-3′; TNF-α forward: 5′-C
TT CTG TCT ACT GAA CTT CGG-3′, reverse: 5′-GTG
CTT GAT CTG TTG TTT CC-3′; GAPDH forward: 5′-A
CC ACA GTC CAT GCC ATC AC-3′, reverse: 5′-TCC
ACC ACC CTG TTG CTG TA-3′. Results in triplicate
were expressed as relative transcriptions of the NF-κB
mRNA and TNF-α mRNA using the following formula:
Folds ¼ 2‐ΔΔCt; ΔΔCt ¼ Ct










Statistical analysis was conducted using SPSS 13.0 soft-
ware package. All data were expressed as mean ± S.D. and
compared using the student’s t-test for two-group analysis
and one-way analysis of variance (ANOVA) followed by
Student-Newman-Keuls method for multiple-group
analysis. Differences in values were considered signifi-
cant at P < 0.05.
Results
Effects of NF-κB siRNA on pulmonary histopathological
changes of LPS-induced ALI rats
We established the lung injury rat model by LPS admin-
istration. Histopathological changes were characterized
by widespread alveolar wall thickness caused by edema,
severe hemorrhage in the alveolus, alveolus collapse and
obvious neutrophil infiltration 1 h after LPS administra-
tion. Furthermore, histopathological changes worsened
at 8 h after LPS administration. On the contrary, lung
tissues from control group exhibited clear and normal
alveolar structures (Fig. 1). We next evaluated the effect
of NF-κB siRNA on pulmonary histopathological
changes of LPS-induced ALI rats and found that imme-
diately intratracheal instillation of NF-κB siRNA effect-
ively attenuated histopathological damage at each time
point (Fig. 1). These data showed that NF-κB siRNA ex-
erts rapid and potent anti-inflammatory effects on lungs
exposed to LPS.
Effects of NF-κB siRNA on the expressions of NF-κB and
NF-κB p65 in lung tissues of LPS-induced ALI rats
We detected the levels of NF-κB mRNA and NF-κB p65
in lung tissues of LPS-induced ALI rats by q-RT-PCR
and Western blot, respectively. At 1 h after LPS expos-
ure, the level of NF-κB mRNA transcription in LPS +
siRNA group was significantly reduced (0.297) compared
with that in LPS + scramble group (0.927). Similarly, at
8 h after LPS exposure, NF-κB transcript levels in LPS +
siRNA group was significantly reduced (0.607) (Fig. 2a).
LPS administration caused a notable increase in NF-κB
p65 protein levels compared with control group at each
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time point. However, in siRNA group, immediately fol-
lowing intratracheal instillation of NF-κB siRNA mark-
edly suppressed NF-κB p65 expression. There were no
significant differences of NF-κB p65 expression between
LPS + DEPC group and LPS + scramble group at each
time point (Fig. 2b). Thus, the intratracheal instillation
of NF-κB siRNA led to the strong knockdown of NF-κB
in lung tissues of LPS-induced ALI rats.
Effects of NF-κB siRNA on the rectal temperature, white
blood cell counts, and lung wet/dry weight ratio of
LPS-induced ALI rats
We further examined whether NF-κB siRNA influenced
rectal temperature, white blood cell counts, and lung
wet/dry weight ratio in LPS-induced ALI rats. The rectal
temperature of rats was significantly decreased 1 h after
LPS administration compared with control group. In
contrast, no significant differences among all groups at
8 h were observed. These results indicate that rectal
temperature could fully recover within 8 h after the on-
set of LPS-induced ALI. Immediate intratracheal instilla-
tion of NF-κB siRNA had minimal effect on the changes
induced by LPS (Fig. 3). LPS administration significantly
reduced white blood cell counts at each time point. At
1 h after LPS administration, immediately intratracheal
instillation of NF-κB siRNA did not efficiently increase
white blood cell counts. In contrast, at 8 h after LPS ad-
ministration, it significantly increased white blood cell
counts. There were no significant differences in white
blood cell counts between LPS + DEPC group and LPS+
scramble group at each time point (Fig. 4). Compared
with control group, the lung wet/dry weight ratio was
obviously enhanced after LPS administration at each
time point. Rats with NF-κB siRNA instillation had a re-
duced lung wet/dry weight ratio. No significant differ-
ences in the lung wet/dry weight ratio were observed
between LPS + DEPC group and LPS+ scramble group
at each time point (Fig. 5). The above results showed
that NF-κB siRNA obviously increased white blood cell
counts at 8 h and reduced lung wet/dry weight ratio in
LPS-induced ALI rats.
Effects of NF-κB siRNA on the level of TNF-α mRNA
expression in lung tissues and concentration of TNF-α
in BALF
Finally, we measured the level of TNF-α mRNA in lung
tissue and TNF-α concentration in BALF by qRT-PCR
and ELISA, respectively. At 1 h after LPS administration,
TNF-α transcript levels in LPS + siRNA group were sig-
nificantly reduced (0.278) compared with that in LPS +
scramble group (0.967). Similarly, at 8 h after LPS ad-
ministration, TNF-α transcript levels in LPS + siRNA
group were significantly reduced (0.568) compared with
that in LPS + scramble group (1.034) (Fig. 6a). LPS ad-
ministration significantly increased the concentration of
TNF-α compared with control group. Immediate intra-
tracheal instillation of NF-κB siRNA partially reversed
this increase. There were no significant differences in
concentrations of TNF-α in BALF between LPS + DEPC
group and LPS + scramble group at each time point
(Fig. 6b). These data suggest that the anti-inflammatory
effects observed after NF-κB’s knockdown may be dir-
ectly associated with the decreased levels of TNF-α.
Fig. 1 NF-κB siRNA preserves lung histology during LPS-induced ALI. Rats were treated with siRNA specific to NF-κB and lung micro-sections were
stained with hematoxylin-eosin to assess histopathological damage at one or eight hours after LPS administration. Pulmonary histopathological
changes of all groups 1 h after saline or LPS administration (a). Pulmonary histopathological changes of all groups 8 h after saline or LPS
administration (b)
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Discussion
Recent years have seen a growth in our understanding of
ALI/ARDS, thus leading to a substantial improvement of
disease outcome upon pharmacological treatment. Sepsis
serves as a leading predisposing factor of ALI and may
be the direct result of the LPS on the outer membrane
of various gram-negative bacteria. Therefore, LPS can be
used to establish ALI animal models through intraven-
ous injection, intraperitoneal injection and intratracheal
instillation [6]. At the present time, clinical trials with
the use of pharmacologic options abound and include
but are not limited to the following [16]: 1, Anti-
endotoxin and anti-cytokine therapy; 2, Anti-adhesion
molecule therapy; 3, Alveolar surfactant replacement
therapy; 4, treatment with glucocorticoids which attenu-
ate fibrosis, among others. Despite numerous options,
glucocorticoids are among the few that have attained
clinical usage. However, their disappointing efficacy in
the acute phase of ALI and increased risk of infection
leaves much to be desired. In the present study, we
undertook the challenge of identifying a novel strategy
that was both effective in the early stages of ALI and de-
void of side effects by using RNA interference.Fig. 2 NF-κB siRNA administration decreased NF-kB transcript and
protein levels in lung tissues of rats with ALI. a qRT-PCR was used to
compare the levels of NF-κB mRNA transcription between LPS +
scramble group and LPS + siRNA group. The amplification of GAPDH
was used as internal control. Data were expressed as mean ± S.D.
from three individual experiments. *P < 0.05 vs. LPS+. b Rats were
treated with siRNA specific to NF-κB for one or eight hours, lung
tissue was collected and processed by western blot analysis to determine
the levels of NF-κB p65 expression after one or eight hours
Fig. 3 NF-κB siRNA changes rectal temperature after LPS
administration. Rectal temperature was measured after ALI induction
and changes tracked at zero, 1 or 8 h. Changes in rectal temperature
were calculated at each time point and presented as the mean
of differences in temperature. Data were expressed as mean ±
S.D. (n = 12). *P < 0.05 vs. saline + DEPC
Fig. 4 NF-κB siRNA alters white blood cell counts after LPS
administration. Rats were treated with siRNA specific to NF-κB; blood
was collected and processed to assess total WBC. Data were expressed
as mean ± S.D. (n = 12). *P < 0.05 vs. saline + DEPC;#P < 0.05 vs. LPS +
DEPC;△P < 0.05 vs. LPS + scramble
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Taking advantage of the siRNA technology that has been
optimized and made highly efficient in the past decade;
we substantiated that intratracheal instillation of NF-κB
siRNA exerted rapid and potent anti-inflammatory effects
on lungs exposed to LPS. The key of RNA interference
(RNAi) lies in delivery and stable expression of siRNA and
has been used to cure disorders of the eyes, lungs and cen-
tral nervous systems [1, 2, 4, 20, 21]. Bitko et. al for the
first time demonstrated that intranasal instillation of
siRNA free of transfection reagents exerted a robustly
anti-inflammatory effect on individual as well as joint in-
fection by respiratory syncytial virus (RSV) and parainflu-
enza virus (PIV), and that when properly designed; direct
siRNA administration turns out to be feasible in the treat-
ment of lung diseases. Moreover, this method displays
many advantages [1]. First, direct siRNA administration
through the respiratory system is relatively simple, nonin-
vasive, and compatible with an inhaler or mist based ther-
apy. Second, the exclusion of a virus-based carrier in this
method reduces the potential risk of carrier side effect.
Therefore, we employed intratracheal instillation of siRNA
to curb the NF-κB pathway activation. As shown in Fig. 2a
and b, we were able to effectively target and significantly
decrease NF-kB levels in our preclinical model. By using
the highly specific siRNA approach, we were able to de-
crease the detectable levels of NF-kB after LPS adminis-
tration in rat lungs at 1 and 8 h intervals. These results
show that specific siRNA targeting of NF-kB can be ac-
complished and thus help establish and validate our pre-
clinical model.
To further investigate the effectiveness on NF-kB
knock down on lung histology, we treated rats with LPS,
siRNA or control. Our data demonstrate that upon ALI
induction followed by siRNA, the level of lung injury
can be significantly altered (Fig. 1). In addition to de-
creasing lung injury, NF-kB knockdown also resulted in
a remarkable decline in lung wet/dry weight ratio (Fig. 5).
Multiple attempts have been made through the years to
suppress ALI by blocking NF-κB pathway, including
stabilization of IκBα [8, 9, 11, 12], inhibition of binding
between activated NF-κB dimers and target genes via
decoy oligonucleotides [3], and transcriptional inhibition
Fig. 5 NF-κB depletion alters lung wet/dry weight ratios after LPS
administration. Rats were treated with siRNA specific to NF-κB and
lung tissue was collected and processed to assess the wet to
dry ratio at one or eight hours. Data were expressed as mean ±
S.D. (n = 12). *P < 0.05 vs. saline + DEPC;#P < 0.05 vs. LPS +
DEPC;△P < 0.05 vs. LPS + scramble
Fig. 6 Specific targeting of NF-κB ablates TNF-α transcript and
protein levels in lung tissue. Rats were treated with siRNA specific to
NF-κB and TNF-α transcript levels were assessed at 1 and 8 h by qRT-
PCR and compared between LPS + scramble group and LPS + siRNA
group (a). The amplification of GAPDH was used as internal control.
Data were expressed as mean ± S.D. from three individual experiments.
#P < 0.05 vs. scramble group. Rats were treated with siRNA specific to
NF-κB and TNF-α levels were assessed at one and eight hrs by standard
ELISA (b). Data were expressed as mean ± S.D. (n = 12). *P < 0.05 vs.
saline + DEPC;#P < 0.05 vs. LPS + DEPC;△P < 0.05 vs. LPS + scramble
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of key components of the NF-κB pathway via antisense
technology [17]. Recently, drugs such as butyrate [14]
and pitavastatin [19] were found to be effective in pre-
venting the initiation of ALI by interacting with NF-κB
pathway. These attempts, however, have limited clinical
merit primarily because they cannot specifically block
the NF-κB pathway without impairing other cellular
activities, leading to known and unknown side effects.
Furthermore, the necessary pretreatment is also a
bottleneck in clinical practice. In contrast, the high
specificity of siRNA without the need of pretreatment
in our study makes it a more ideal strategy compared
with other methods. Taken together, our data repre-
sent a novel and highly effective way to specifically
target NF-kB, reduce lung injury while minimizing
detrimental and unwanted side effects.
Cells of the immune system are key producers of cyto-
kines in response to a plethora of immunologic insults.
NF-kB has been shown to be a key regulator of many
immunologic responses [7]. To this end, we wanted to
determine the effects of NF-kB targeting on total white
blood cells counts. Indeed, knock down of NF-kB re-
sulted in the amelioration of white blood cell counts 8 h
after LPS administration (Fig. 4). Our results are in line
with previously published reports and further provide
evidence for the central role of NF-kB in ALI and im-
munity [9, 10].
Given its impact on immunologic function and cyto-
kine production, we next wanted to assess whether NF-
kB targeting would also alter cytokine production. As
seen in Fig. 6a and b, NF-κB siRNA effectively sup-
pressed levels of TNF-α mRNA transcription and con-
centrations of TNF-α in BALF, providing evidence to
support the possibility that the mechanism of NF-κB
siRNA’s anti-inflammatory effects is likely associated
with the reduction of proinflammatory cytokines. TNF-
α, however, can be regulated by other pathways, and
should e further investigated but are beyond the scope
of this manuscript [9].
Conclusion
In conclusion, NF-κB specific knockdown exerts its anti-
inflammatory effects on LPS-induced ALI likely because
of a reduction of the proinflammatory cytokine, TNF-a.
Therefore, we offer the following; NF-κB siRNA treat-
ment represents an effective and novel strategy for
modulating inflammatory response for ALI in the early
stages with high clinical relevancy. One important point
is that we acknowledge that a limitation of the study is
the direct translational implications of our findings as
NF-κB siRNA treatment in humans would represent a
significant challenge given that clinical symptoms appear
much later then the time points investigated here.
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